Erba Unveils New H 7100 Advanced Hematology Analyzer

This state-of-the-art diagnostic instrument promises a paradigm shift in blood analysis capabilities, catering to the complex needs of clinical laboratories and research facilities.

Hematology analyzers are revolutionizing modern clinical labs, delivering crucial insights into blood composition for diagnosing and monitoring various disorders. With technological advancements, these tools now offer enhanced performance, accuracy, and efficiency. The H 7100 is a breakthrough in hematology diagnostics, redefining the field by enabling rapid, reliable insights for clinicians and enhancing diagnostic accuracy and research capabilities. Equipped with fluorescence flow cytometry technology, the H 7100 has a 70-parameter range including Reticulocytes, Immature Platelet Fraction (IPF) and Immature Granulocytes (IG). These are critical for diagnosing, monitoring and treating conditions like anemia, thrombocytopenia, infection, inflammation and myeloid neoplasms. It offers real-time insights of response to allergic leukemia, anemia, bone marrow failure syndromes and hemolytic disorders.

With its advanced algorithms improving clinical decision-making and patient care, the H 7100 redefines the hematology diagnostics space by enabling rapid, reliable insights for clinicians and enhancing diagnostic accuracy and research capabilities in the field. The H7100 sets itself apart with a throughput of 90 tests per hour for CBC+diff and 70 tests per hour for CBC+Diff+retics. Fully automated, it can become a 2X system by adding additional units and samplers. Its Mentzer Index feature helps differentiate between Iron Deficiency Anemia (IDA) and Beta Thalassemia while its Optical Platelet (Plt-O) feature addresses challenges like pseudo-thrombocytopenia in hematological analysis. Optical platelet count reduces the spurious count and is useful in correcting spurious low platelet counts in EDTA-PTCP patients. Cost-effective and minimizing reagent usage, the H7100 is ideal for large and medium-sized labs, corporate hospitals, and B2B labs.